Lyell Immunopharma
LYEL12.9900.23% ( +0.030 )
Lyell Immunopharma (LYEL)
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologi...
- Open
- 12.940
- High
- 13.050
- Low
- 12.560
- Prev. Close
- 12.960
- Volume
- 157.08K
- Turnover
- 2.03M
- Avg Price
- 12.952
- Bid/Ask Ratio
- --
- Amplitude
- 3.78%
- 52wk High
- 45.000
- Volume Ratio
- 1.29
- Turnover Ratio
- 1.46%
Lyell Immunopharma Analyst Rating
View MoreForecast & Rating
Jul 22, 2026Price forecast
$38.14193.63%
Forecast & RatingBuy
7analysts
- Strong buy57.14%
- Buy28.57%
- Hold0.00%
- Sell0.00%
- Strong sell14.29%
News
- PUBT · Jul 20 at 01:56 PM
Innovative Cellular Therapeutics Holdings reports Lyell Immunopharma share sale worth $137
- Market Beat · Jul 19 at 03:14 AM
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Given Consensus Rating of "Moderate Buy" by Brokerages
- PUBT · Jul 17 at 08:45 PM
Innovative Cellular Therapeutics Holdings reports Lyell Immunopharma common share disposal worth $137.3
- benzinga_article · Jul 6 at 07:05 AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
- PUBT · Jun 18 at 03:07 PM
Lyell Immunopharma initial beneficial ownership filing names Innovative Cellular Therapeutics Holdings as 10% owner
- StockTitan · Jun 12 at 03:45 AM
Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress | LYEL Stock News
